3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Conditions
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors, Primitive
1
Neoplasms
1
Lung Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoid Tumor
1
Interventions
Octreotide
5
Everolimus
4
pasireotide
3
lanreotide
3
ganitumab
2
gallium Ga 68 dotatate
2
cabozantinib
2
Nivolumab
2
Erlotinib Hydrochloride
2
surufatinib
1
pertuzumab
1
nintedanib
1
ibrutinib
1
fosbretabulin
1
conatumumab
1
cixutumumab
1
carfilzomib
1
arginyllysine
1
aflibercept
1
Temozolomide
1
Sunitinib
1
Somatostatin
1
Random Allocation
1
Ramucirumab
1
Magnetic Resonance Spectroscopy
1
Ipilimumab
1
Capecitabine
1
Bevacizumab
1
Axitinib
1
(18F)GTP1
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Carcinoid Tumor
×
fosbretabulin
×
Clear all
NCT02132468
2017-12-05
GI-NETorPNET
Mateon Therapeutics
Phase 2
Completed
18 enrolled
10 charts